AI assistant
Zelluna ASA — Share Issue/Capital Change 2021
Oct 12, 2021
3779_rns_2021-10-12_5b5f9f02-4468-4204-b69b-83b77eae405a.html
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Ultimovacs ASA: Share capital increase related to exercise of options
Ultimovacs ASA: Share capital increase related to exercise of options
Oslo, 12 October 2021, the Board of Directors of Ultimovacs ASA (the "Company")
has resolved to increase the Company's share capital by NOK 5,850 through the
issuance of 58,500 new shares, each with a par value of NOK 0.10. The resolution
is based on an authorisation to increase the share capital granted by the
Company's general meeting on 15 April 2021.
The new shares are issued to employees of the Company in connection with the
Company's employee incentive program. 45,000 of the new shares are issued at a
subscription price of NOK 31.25, and 13,500 shares at a subscription price of
NOK 39.15.
Following registration of the share capital increase with the Norwegian Register
of Business Enterprises, the Company will have a share capital of NOK
3,206,176.10, divided into 32,061,761 shares, each with a par value of NOK
0.10.
For further information, please contact:
Jónas Einarsson, Chairman of the Board of Directors of Ultimovacs ASA
Email: [email protected]
Phone: +47 480 96 355
Carlos de Sousa, CEO
Email: [email protected]
Phone: +47 908 92507
Hans Vassgård Eid, CFO
Email: [email protected]
Phone: +47 482 48632